Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Areteia Therapeutics Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units. PURDY, KYLE A is the busiest examiner, currently managing 1 pending office action. The distribution across different art units suggests that the portfolio covers varied technical aspects within the broader biotechnology field, requiring review from multiple specialized groups.
Because there are 2 pending office actions and 2 distinct examiners, the company must manage 2 separate prosecution tracks. This lack of concentration means that the outcomes are not dependent on 1 examiner's discretion. Practitioners must adapt to the different styles of the 2 distinct examiners and the specific standards of the 2 distinct art units involved. This dispersion increases the complexity of the portfolio compared to a structure with only 1 distinct art unit. However, it also reflects a broader technical footprint for the company's pharmaceutical filings, as each action is being evaluated by a different set of experts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PURDY, KYLE A | 1 | 41.0% | +35.7% |
| VIGIL, TORIANA NICHOLE | 1 | 52.9% | +26.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18990646 | OSMOTIC TABLETS OF DEXPRAMIPEXOLE AND METHODS OF MANUFACTURING AND USE THEREOF | PURDY, KYLE A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18990646 | OSMOTIC TABLETS OF DEXPRAMIPEXOLE AND METHODS OF MANUFACTURING AND USE THEREOF | PURDY, KYLE A | — |
| 18988479 | USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF INADEQUATELY CONTROLLED MODERATE TO SEVERE ASTHMA | VIGIL, TORIANA NICHOLE | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18990646 | OSMOTIC TABLETS OF DEXPRAMIPEXOLE AND METHODS OF MANUFACTURING AND USE THEREOF | PURDY, KYLE A | 1611 | §103§112 | Non-Final OA | — | Pending | Dec 20, 2024 |
| 18988479 | USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF INADEQUATELY CONTROLLED MODERATE TO SEVERE ASTHMA | VIGIL, TORIANA NICHOLE | 1612 | §102§103DP | Non-Final OA | — | Pending | Dec 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAreteia Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Kyle A Purdy has the most, with 1 of Areteia Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
